Literature DB >> 30074820

Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Scott M Thompson1, Ishan Garg1, Eric C Ehman1, Shannon P Sheedy1, Candice A Bookwalter1, Rickey E Carter2, Lewis R Roberts3, Sudhakar K Venkatesh1.   

Abstract

OBJECTIVE: : To evaluate the effect of hepatic steatosis on LI-RADS® major features at MRI in patients with non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC).
METHODS: : HCC and liver parenchyma features at MRI from 48 consecutive patients with NAFLD and histology proven HCC (mean ± SD; 4.5 ± 3.4 cm) were independently reviewed by three radiologists. Inter-rater agreement was determined by prevalence/bias-adjusted kappa. Hepatic fat signal fraction (FS%) was independently calculated. HCC features were compared by FS% at MRI using logistic regression analysis and histologic steatosis grade using Cochran-Armitage test for trend, stratified by cirrhotic liver morphology or histologic fibrosis stage. Receiver operating characteristic curves were generated to determine the sensitivity and specificity for major HCC features by FS%.
RESULTS: : Major HCC features included arterial phase hyperenhancement (APHE) in 45 (93%), portal venous phase washout (PVWO) in 30 (63%), delayed phase washout (DPWO) in 38 (79%) and enhancing "capsule" in 34 (71%). Cirrhotic morphology was present in 22 (46%). Inter-rater agreement was 0.75 for APHE, 0.42-0.58 for PVWO, 0.58-0.71 for DPWO and 0.38-0.67 for enhancing "capsule". There was an 18%, 14% and 22% increase in the odds of absent PVWO, DPWO and capsule appearance for every 1% increase in hepatic FS% in patients with non-cirrhotic liver morphology (p = 0.011, 0.040 and 0.029, respectively). Hepatic FS% ≥ 14.8% had a sensitivity and specificity of 64 and 100% for absent PVWO and 71 and 90% for absent DPWO in patients with non-cirrhotic liver morphology.
CONCLUSION: : Absent washout and capsule appearance are associated with increasing hepatic steatosis in patients with non-cirrhotic, NAFLD-associated HCC. ADVANCES IN KNOWLEDGE:: In patients with non-cirrhotic, non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC), absent HCC washout and capsule appearance are associated with increasing hepatic steatosis, thereby potentially impacting the noninvasive imaging diagnosis of HCC in these patients. Lack of washout or capsule appearance in steatotic livers at MRI may require alternative criteria for the diagnosis of HCC in patients with non-cirrhotic NAFLD.

Entities:  

Mesh:

Year:  2018        PMID: 30074820      PMCID: PMC6319849          DOI: 10.1259/bjr.20180345

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  53 in total

1.  Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity.

Authors:  A B Rosenkrantz; L Lee; B W Matza; S Kim
Journal:  Clin Radiol       Date:  2012-09-29       Impact factor: 2.350

2.  Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma.

Authors:  Abdirashid M Shire; Dalbir S Sandhu; Joseph K Kaiya; Abdul M Oseini; Ju Dong Yang; Roongruedee Chaiteerakij; Teresa A Mettler; Nasra H Giama; Rosebud O Roberts; Terry M Therneau; Gloria M Petersen; Keith L Knutson; Lewis R Roberts
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

3.  Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy.

Authors:  Eric C Ehman; Sarah E Umetsu; Michael A Ohliger; Nicholas Fidelman; Linda D Ferrell; Ben M Yeh; Judy Yee; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2016-11

4.  Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

Authors:  Judith Ertle; Alexander Dechêne; Jan-Peter Sowa; Volker Penndorf; Kerstin Herzer; Gernot Kaiser; Jörg F Schlaak; Guido Gerken; Wing-Kin Syn; Ali Canbay
Journal:  Int J Cancer       Date:  2011-03-14       Impact factor: 7.396

5.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

6.  Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.

Authors:  Eric C Ehman; Spencer C Behr; Sarah E Umetsu; Nicholas Fidelman; Ben M Yeh; Linda D Ferrell; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2016-05

7.  Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Shahid M Malik; Parijat A Gupte; Michael E de Vera; Jawad Ahmad
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-09       Impact factor: 11.382

8.  Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation.

Authors:  Hyun-Jung Jang; Tae Kyoung Kim; Peter N Burns; Stephanie R Wilson
Journal:  Radiology       Date:  2007-09       Impact factor: 11.105

9.  Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease.

Authors:  An Tang; Ajinkya Desai; Gavin Hamilton; Tanya Wolfson; Anthony Gamst; Jessica Lam; Lisa Clark; Jonathan Hooker; Tanya Chavez; Brandon D Ang; Michael S Middleton; Michael Peterson; Rohit Loomba; Claude B Sirlin
Journal:  Radiology       Date:  2014-09-22       Impact factor: 11.105

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  3 in total

Review 1.  Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances.

Authors:  Hao Qin; Baowen Yuan; Wei Huang; Yan Wang
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

Review 2.  Current Imaging Diagnosis of Hepatocellular Carcinoma.

Authors:  Evangelos Chartampilas; Vasileios Rafailidis; Vivian Georgopoulou; Georgios Kalarakis; Adam Hatzidakis; Panos Prassopoulos
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

Review 3.  Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.

Authors:  Lampros Chrysavgis; Ilias Giannakodimos; Panagiota Diamantopoulou; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2022-01-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.